lymphoma/nudności

Link zostanie zapisany w schowku

Wybierz rodzaj sortowania

Strona 1 od 981 wyniki

A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND Chemotherapy-induced nausea and vomiting (CINV) is a troublesome issue in chemotherapy for cancer patients. A second-generation 5HT3 receptor antagonist (5HT3RA), palonosetron, is effective and safe for the prevention of CINV in breast cancer patients treated with cyclophosphamide and

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

OBJECTIVE The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

Antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with non-Hodgkin lymphoma (NHL) receiving moderately emetogenic chemotherapy (MEC) generally includes a serotonin-type 3 (5-HT3) receptor antagonist (RA). The efficacy and safety of the second-generation 5-HT3 RA,

[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma. The impact of the prognosis announcement on the anti-emetic effect and chemotherapy-associated adverse events was

Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

Few studies have investigated the effect of palonosetron on delayed chemotherapy-induced nausea and vomiting in lymphoma patients receiving the CHOP regimen. We conducted a prospective clinical trial to assess the efficacy of palonosetron in patients receiving the CHOP regimen. Complete control (CC:

Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

Standard-dose (2 mg/day) oral granisetron seems to have more antiemetic efficacy than that of high-dose (0.5-1 mg/kg/dose) metoclopramide in moderately emetogenic chemotherapy. However, the cost of oral granisetron is much higher than that of metoclopramide so the authors tried to overcome this

[Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

The antiemetic effect of granisetron on nausea and vomiting induced by cancer chemotherapy (CHOP, VEPA, VEPA-B, massive dose of ETP) was studied in fifty patients with non-Hodgkin's lymphoma. There was almost no difference in the inhibitory effect by regimen, with the rates of perfect inhibition of

A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

Chemotherapy-induced nausea and vomiting (CINV) is a serious problem for cancer patients receiving chemotherapy. The CHOP regimen is the standard treatment for non-Hodgkin's lymphoma (NHL) and is categorized as highly or moderately emetogenic in the CINV guidelines. The efficacy of oral 5-HT3

Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV). Therefore, it is important to adjust the anti-emetic regimens based on personal risk factors of the patient, duration of the

Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin's lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric,

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. However, its optimal use for antiemetic therapy has not been established yet. We assessed the efficacy of

Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

Chemotherapy-induced nausea and vomiting (CINV) is a distressing treatment side-effect that could negatively affect children's quality of life (QoL). Different scoring systems for CINV were applied and different antiemetic drugs were used; however, few studies have been performed in children

Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND The current standard for prevention of chemotherapy-induced nausea/vomiting in autologous stem cell transplant only achieves 4-20% emetic control. OBJECTIVE To assess emetic responses to multiday palonosetron, aprepitant, and low-dose dexamethasone among patients with myeloma and lymphoma

Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

Despite the availability of several antiemetics, clinical findings show that control of chemotherapy-induced nausea and vomiting (CINV) continues to be a serious concern for hematological patients, mainly for those receiving multiple-day (MD) and high-dose (HD) chemotherapy (CT). For CINV

Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

We performed a prospective study to investigate the efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone in non-Hodgkin lymphoma patients receiving R-CEOP or CEOP chemotherapy regimen. All patients were randomly assigned to either an aprepitant regimen (aprepitant plus

Poprzedni
1
2
3
4
5
6
...
65
66
Kolejny

Dołącz do naszej strony
na Facebooku

Herbal & Natural Medicine

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo

Działa w 55 językach
Ziołowe leki poparte nauką
Rozpoznawanie ziół na podstawie obrazu
Interaktywna mapa GPS - oznacz zioła na miejscu (wkrótce)
Przeczytaj publikacje naukowe związane z Twoim wyszukiwaniem
Szukaj ziół leczniczych po ich działaniu
Uporządkuj swoje zainteresowania i bądź na bieżąco z nowościami, badaniami klinicznymi i patentami

Wpisz objaw lub chorobę i przeczytaj o ziołach, które mogą pomóc, wpisz zioło i zobacz choroby i objawy, na które są stosowane.
* Wszystkie informacje oparte są na opublikowanych badaniach naukowych